ests by $400M to $2.88 for 2014E. While Avonex does face volume declines, price and market share gains have kept revs flat. We expect the launch of Plegridy (approved in EU today and US expected in 2H) to accelerate share gains which should continue to keep franchise revs flat Y/Y. And on Tysabri, underl